# Expedition Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/expedition-therapeutics-2

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.expeditiontx.com
- Total disclosed funding: $165M
- Latest round: Series A (Oct 9, 2025)
- Investors on record: 8

## About

Expedition Therapeutics Inc. is a biopharmaceutical company focused on developing innovative solutions for inflammatory and respiratory diseases, particularly chronic obstructive pulmonary disease (COPD).Founded in 2024 in San Francisco, US, Expedition Therapeutics Inc. is dedicated to developing therapies for inflammatory and respiratory diseases. The company is privately held and has raised USD 165 mn in its Series A funding round on October 9, 2025, co-led by Novo Holdings and Sofinnova Investments, along with several other investors. The founder's information is not readily available, and there is no indication of previous companies founded by the individuals involved.Expedition Therapeutics focuses on developing innovative treatments specifically targeting inflammatory and respiratory diseases, primarily chronic obstructive pulmonary disease (COPD). Their lead product, EXPD-101, is an oral DPP1 inhibitor designed to address neutrophilic inflammation—an underlying mechanism that exacerbates tissue damage and lung function decline in COPD patients. The therapy aims to provide a disease-controlling option for nearly 70% of COPD patients who currently lack effective treatment alternatives. Additionally, the company is exploring the potential of EXPD-101 in related conditions such as bronchiectasis and neutrophilic asthma, thereby broadening its applicability. Expedition Therapeutics targets both the North American and European markets, seeking to deliver its advanced therapeutic solutions to a wide range of healthcare providers and patients globally.Expedition Therapeutics recently completed a substantial USD 165 mn Series A financing round, indicating strong investor confidence and support for the company’s mission. Revenue generation primarily revolves around partnerships and collaborations with pharmaceutical companies, healthcare providers, and research institutions that seek to leverage their innovative therapies. The transactions are expected to be structured around licensing agreements, clinical trial collaborations, and potentially direct sales once products receive regulatory approval and market entry. Flagship product EXPD-101 is anticipated to be central to these revenue streams, as it transitions into further clinical trials and prepares for commercialization.In October 2025, Expedition Therapeutics Inc. raised USD 165 mn in Series A funding, which the company will utilize to conduct clinical trials for its lead drug EXPD-101, expand research efforts, and support regulatory approval. The company is also focused on expanding its market reach in North America and Europe, aiming for broader access to its therapeutic solutions as it progresses through clinical development.

## Funding rounds

- Series A, Oct 9, 2025, $165M — Sofinnova Investments, Novo Holdings, Forbion, Sanofi Ventures, BVF Partners, Logos Capital, Venrock Healthcare Capital Partners
- Seed, Mar 25, 2025 — BVF Partners, Lake Bleu Capital, Venrock Healthcare Capital Partners

## Investors

- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Seed, Series A
- Lake Bleu Capital (https://capitalatlas.ai/funds/lake-bleu-capital) — Seed
- Venrock Healthcare Capital Partners (https://capitalatlas.ai/funds/venrock-healthcare-capital-partners) — Seed, Series A
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series A
- Novo Holdings — Series A
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series A
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series A